Management Team

Dr. Donald S. Masters, President and CEO

Donald S. MastersDr. Masters is President and Chief Executive Officer of Artificial Cell Technologies. His twenty-nine year career began as a member of the Harvard-Monsanto Project that led to the development of the Biotechnology industry. He left Harvard to become the fifth employee at Genzyme, creating their successful Research Biologicals business unit which was eventually sold for $67 million. He left Genzyme to become the founding CEO of OxiGene, which is now a public company. Following his tenure at OxiGene he became involved in the information technology field, heading up the Biological Applications Program at TASC, Inc. a $300 million per year information technology company, and TechEx a B2B exchange connecting University technology transfer offices to pharmaceutical companies which he successfully sold in 2002. After a period as a Principal at Commonwealth Pharmaceutical Partners, a business development consultancy and affiliate of the Medical Science Partners venture capital fund, he returned to the Biotech CEO ranks, heading up three start-ups: Bion, Inc, C3 Scientific Corporation and Esperance Pharmaceuticals. Dr. Masters became CEO in July of 2008.

Dr. Masters graduated from The Johns Hopkins University with a degree in Biophysics, received his Ph.D. in Biochemistry and Immunology from Cornell University Medical College and was a Post-doctoral Fellow at Harvard Medical School.
Thomas P. Malone, CFO and VP of Regulatory Affairs

Thomas P. MaloneMr. Malone was the founding CEO of Artificial Cell Technologies, successfully raising several million dollars in initial seed stage capital, establishing R&D operations in CT, and leading development of the IP portfolio. He has 20 years’ experience as an entrepreneur, executive, and management strategy consultant. Previously Mr. Malone served as Senior Vice President, College of American Pathologists (CAP), the second largest medical association in the United States and the leading provider of quality assurance services to the laboratory medicine industry. Earlier in his career he was a Senior Manager in the Strategy and Business Architecture Practice of Accenture, consulting to and managing consulting engagements for c-level executives of Global 500 companies to design and implement better business and operating strategies. He served as Accenture’s Global Segment Lead for the Consumer Electronics Industry Segment for several years.

Mr. Malone graduated from the Georgia Institute of Technology with a BS in Physics, from Georgia State University with a BS in Economics, magna cum laude, and received his MBA in General Management and Finance from the University of Chicago Booth School of Business.
Dr. Jeff Powell, VP of Immunology

Jeff PowellDr. Powell joined the Company in 2009. He previously served as Vice President of Research at VaxInnate Corporation, which he joined at its founding in 2002. At VaxInnate, Dr. Powell managed all aspects of discovery research and candidate evaluation and selection. Under his leadership, the research team delivered multiple vaccine candidates including two novel influenza vaccines currently undergoing clinical evaluation. Dr. Powell also led vaccine research efforts in other disease indications including respiratory syncytial virus (RSV), Dengue virus, and malaria. He was responsible for raising $18 million of grant and contract funding from the NIH, the Department of Defense, and the Bill and Melinda Gates Foundation. Prior to VaxInnate, Dr. Powell held research and management positions at SUGEN, Inc., and CuraGen Corporation.

Dr. Powell received his Ph.D. in Molecular and Cell Biology from the University of Alabama at Birmingham, and was a postdoctoral fellow in the Department of Microbiology & Immunology at the University of Miami School of Medicine.
Dr. Jim Boyd, VP of Chemistry

Jim BoydDr. Boyd joined the ACT team in early 2009 charged with setting up a lab specializing in peptide chemistry and microparticle vaccine fabrication.  Prior to that he was at Pfizer Inc. in Groton, CT where he led a wide variety of peptide and peptidomimetic drug discovery projects.  Most notably his lab developed a series of selective and highly potent low molecular weight peptidomimetic inhibitors of beta-secretase (BACE).  In addition, he played a critical role in the development of modified peptide hormones that regulate feeding behavior in mammals, one of which was chosen for human clinical trials.  Prior to that Jim was at Repligen Corporation where he synthesized peptide bioconjugates as prototype HIV vaccine candidates.

Jim received his Ph.D. in Organic Chemistry from the Massachusetts Institute of Technology where he researched peptide conformation and secondary structure biases. 

ACT's management team includes: